Exploring the Advantages of Quantum Generative Adversarial Networks in Generative Chemistry.

Journal: Journal of chemical information and modeling
PMID:

Abstract

De novo drug design with desired biological activities is crucial for developing novel therapeutics for patients. The drug development process is time- and resource-consuming, and it has a low probability of success. Recent advances in machine learning and deep learning technology have reduced the time and cost of the discovery process and therefore, improved pharmaceutical research and development. In this paper, we explore the combination of two rapidly developing fields with lead candidate discovery in the drug development process. First, artificial intelligence has already been demonstrated to successfully accelerate conventional drug design approaches. Second, quantum computing has demonstrated promising potential in different applications, such as quantum chemistry, combinatorial optimizations, and machine learning. This article explores hybrid quantum-classical generative adversarial networks (GAN) for small molecule discovery. We substituted each element of GAN with a variational quantum circuit (VQC) and demonstrated the quantum advantages in the small drug discovery. Utilizing a VQC in the noise generator of a GAN to generate small molecules achieves better physicochemical properties and performance in the goal-directed benchmark than the classical counterpart. Moreover, we demonstrate the potential of a VQC with only tens of learnable parameters in the generator of GAN to generate small molecules. We also demonstrate the quantum advantage of a VQC in the discriminator of GAN. In this hybrid model, the number of learnable parameters is significantly less than the classical ones, and it can still generate valid molecules. The hybrid model with only tens of training parameters in the quantum discriminator outperforms the MLP-based one in terms of both generated molecule properties and the achieved KL divergence. However, the hybrid quantum-classical GANs still face challenges in generating unique and valid molecules compared to their classical counterparts.

Authors

  • Po-Yu Kao
    Insilico Medicine Taiwan Ltd., Taipei 110208, Taiwan.
  • Ya-Chu Yang
    Insilico Medicine Taiwan Ltd., Taipei 110208, Taiwan.
  • Wei-Yin Chiang
    Hon Hai (Foxconn) Research Institute, Taipei 114699, Taiwan.
  • Jen-Yueh Hsiao
    Hon Hai (Foxconn) Research Institute, Taipei 114699, Taiwan.
  • Yudong Cao
    Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, United States of America.
  • Alex Aliper
    Pharma.AI Department , Insilico Medicine, Inc. , Baltimore , Maryland 21218 , United States.
  • Feng Ren
    Insilico Medicine Hong Kong Ltd., Hong Kong Science and Technology Park, New Territories, Hong Kong, China.
  • Alán Aspuru-Guzik
    Departments of Chemistry, Computer Science, University of Toronto St. George Campus Toronto ON Canada.
  • Alex Zhavoronkov
    Pharmaceutical Artificial Intelligence Department, Insilico Medicine, Inc., Emerging Technology Centers, Johns Hopkins University at Eastern, Baltimore, Maryland, USA.
  • Min-Hsiu Hsieh
    Hon Hai (Foxconn) Research Institute, Taipei 114699, Taiwan.
  • Yen-Chu Lin
    Insilico Medicine Taiwan Ltd., Taipei 110208, Taiwan.